AI chatbot support for substance use recovery
A Conversational Agent to Support Follow-up Care for Individuals in Recovery for Substance Use Disorder
This study tests whether an AI chatbot can help people recovering from opioid use disorder by providing support and resources over 12 weeks.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 55 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Dimagi Inc. Industry-sponsored |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06845878 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of an AI chatbot designed to assist patients recovering from opioid use disorder. Participants will have access to the chatbot for 12 weeks, which will help them prepare for clinical appointments, find community resources, and learn recovery techniques. The study will assess the chatbot's impact on reducing drug use, improving appointment adherence, and enhancing patients' self-efficacy in their recovery journey. Feedback from participants will also be collected to gauge the chatbot's usability and effectiveness.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 who are receiving medication treatment for opioid use disorder and are comfortable using mobile technology.
Not a fit: Patients with cognitive, visual, or auditory impairments that hinder their ability to use the chatbot may not benefit from this study.
Why it matters
Potential benefit: If successful, this chatbot could provide a valuable tool for patients in recovery, enhancing their support and resources.
How similar studies have performed: While the use of chatbots in healthcare is emerging, this specific approach for supporting opioid use recovery is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-65 years old * Comfortable with reading, understanding, and communicating in English * Receiving medication treatment for OUD at MGH? * Able to participate in a remote interview? * Own or have reliable access to Wi-Fi or a cellular network * Willing to use a mobile device to access the chatbot? Exclusion Criteria: * Has any cognitive, visual, or auditory impairments that may prevent the participant from using the chatbot on a mobile device? * Unstable medical condition that compromises the ability to safely participate
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Y. Xian Ho, PhD — Dimagi Inc.
- Study coordinator: Dimagi Study Team
- Email: studies@dimagi.com
- Phone: 617-649-2214
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.